| Literature DB >> 30344701 |
Junko Masuda1,2, Eiji Takayama3, Tatsuo Ichinohe4, Warren Strober2, Masako Mizuno-Kamiya3, Tomokatsu Ikawa5, Atsushi Kitani2, Harumi Kawaki3, Ivan Fuss2, Hiroshi Kawamoto6, Akimasa Seno1, Arun Vaidyanath1, Naoki Umemura3, Akifumi Mizutani1, Tomonari Kasai1, Yasuko Honjo4, Ayano Satoh1, Hiroshi Murakami1, Yoshimoto Katsura6, Nobuo Kondoh3, Masaharu Seno1.
Abstract
Administration of bone marrow-derived mesenchymal stem cells (MSCs) is a possible treatment for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation and other inflammatory conditions. To address the mechanism of immunosuppression by MSCs, in particular those derived from adipose tissue (AMSCs), AMSCs were isolated from three different mouse strains, and the suppressive capacity of the AMSCs thus obtained to suppress interferon (IFN)-γ generation in mixed lymphocyte reaction cultures serving as an in vitro model of GVHD were assessed. It was revealed that the AMSCs had a potent capacity to suppress IFN-γ production regardless of their strain of origin and that such suppression was not associated with production of interleukin-10. In addition, the results demonstrated that β2-microglobulin (β2m)-deficient AMSCs from β2m-/- mice were also potent suppressor cells, verifying the fact that the mechanism underlying the suppression by AMSCs is independent of major histocompatibility complex (MHC) class I expression or MHC compatibility. As AMSCs appear to have immunosuppressive properties, AMSCs may be a useful source of biological suppressor cells for the control of GVHD in humans.Entities:
Keywords: adipose tissue-derived mesenchymal stem cells; graft vs. host disease; major histocompatibility complex class I; β2-microglobulin
Year: 2018 PMID: 30344701 PMCID: PMC6176164 DOI: 10.3892/etm.2018.6689
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447